Results 51 to 60 of about 18,928 (205)
Marshall Journal of Medicine, 2019 Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI.
Ahmed Amro +10 more
doaj +1 more source
Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication
Haematologica, 2015 In patients with acute coronary syndrome, dual antiplatelet therapy with aspirin and a P2Y12 inhibitor like prasugrel is prescribed for one year. Here, we investigated how the hemostatic function of platelets recovers after discontinuation of prasugrel ...
Constance C. F. M. J. Baaten +11 more
doaj +1 more source
Morphine Analgesia Pre-PPCI Is Associated with Prothrombotic State, Reduced Spontaneous Reperfusion and Greater Infarct Size [PDF]
, 2017 Schattauer GmbH Stuttgart.The emergency management of ST-elevation myocardial infarction (STEMI) involves treatment with dual-antiplatelet therapy (DAPT) and primary percutaneous coronary intervention (PPCI). Pain is generally treated with opiates, which
Farag, Mohamed +5 more
core +2 more sources
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu +9 more
wiley +1 more source
Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
Рациональная фармакотерапия в кардиологии, 2020 Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment. The new generation of inhibitors of P2Y12 platelet receptors (prasugrel and ticagrelor) provide more pronounced platelet inhibition than clopidogrel.
T. M. Uskach, A. S. Tereshchenko
doaj +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background The residual Gensini score (rGS) was developed to quantify the severity of coronary atheroma burden after coronary revascularisation. The predictive value of the rGS for clinical outcomes in patients with ST‐segment elevation myocardial infarction (STEMI) remains unexplored.
Batric Popovic +8 more
wiley +1 more source
Journal of Hematology & Oncology, 2013 Background Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet agent, in adult patients with SCD ...
Wun Ted +15 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 Aims: In this pre-specified analysis of the “endothelium, stent and antiplatelet therapy” study, we investigate the impact of antiplatelet therapies on microvascular function in patients undergoing stenting for an acute coronary syndrome.Methods and ...
Boris Schnorbus +7 more
doaj +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background Distal transradial access (dTRA) has gained attention for its lower risk of vascular complications compared to conventional transradial access (TRA). However, its feasibility and safety in patients with out‐of‐hospital cardiac arrest (OHCA) undergoing emergency percutaneous coronary intervention (PCI) remain uncertain.
Shiori Kawakami +9 more
wiley +1 more source
Атеротромбоз, 2018 Prasugrel is a third-generation thienopyridine that provides earlier onset of action, has a reduced probability of insensitivity to the drug, a greater degree of inhibition of ADP-induced platelet aggregation compared to clopidogrel.
O. O. Shakhmatova, A. L. Komarov
doaj +1 more source